The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.632%)
Open: 19.25
High: 19.25
Low: 18.75
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Announces Agreement with Epic Games

25 Jul 2011 07:00

RNS Number : 9301K
Angle PLC
25 July 2011
 



For immediate release

25 July 2011

 

ANGLE plc

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES AGREEMENT WITH EPIC GAMES

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, has joined Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme.

The powerful integration of Geomerics premier cross-platform lighting solution, Enlighten, with Epic's award winning Unreal Engine 3 provides a com--pelling proposition for computer games developers. Through its membership in Epic's Unreal Engine 3 Integrated Partners Programme, Geomerics maintains code and feature parity for Enlighten in step with the engine as it evolves.

Epic's Unreal Engine 3 is designed to accelerate developers' productivity for computer and video games, mobile games and applications, training stimulations, 3D visualisations, digital films and animated televisions shows. Unreal Engine 3 is the current holder and five-time winner of Game Developer magasine's Best Engine award in the US. It is available across multiple platforms including iOS, Xbox360® and Playstation®3, PC, Mac and Android.

Geomerics' Enlighten empowers game developers by providing the ability to update all aspects of indirect lighting in real time, in game, on PC and console. Enlighten is optimised to run on Playstation®3, Xbox 360™ and PC. It is available as a stand-alone SDK, or pre-integrated into UE3.

 

Andrew Newland, Chief Executive of ANGLE commented: 

"This agreement with Epic, one of the world's leading and most successful games developers, is a great endorsement of Geomerics' cutting edge dynamic lighting technology. Association with Epic with its established customer base and trusted industry relationships can only be beneficial for Geomerics as it continues to grow its sales base."

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon, Catherine Breen

 

0207 466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

About Epic Games

Epic Games, Inc., based in Cary, NC and established in 1991, develops cutting-edge games and cross-platform game engine technology. The company has created multiple million-selling, award-winning titles in its "Unreal" series, including "Unreal Tournament 3" for PC, PlayStation®3 and Xbox 360®. Epic's "Gears of War" franchise has sold more than 13 million copies worldwide and won more than 50 Game of the Year awards. Epic's Unreal Engine 3 is the five-time winner of and Hall of Fame inductee for Game Developer magazine's Best Engine Front Line Award. Unreal Engine 3 has also held the Develop Industry Excellence Award in its category for the past three years. Additional information about Epic can be obtained at www.epicgames.com.

 

About Geomerics

Geomerics, a 33% owned ANGLE portfolio company, is an innovation-led company developing cutting-edge graphics technology for the games industry. The company is based in Cambridge, UK, and has built a team that combines world class management and games industry experience with some of the UK's leading researchers. They are partners with many of the leading companies in the games industry and are currently working with developers around the world on AAA titles for release in 2011 and beyond.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFESDVIFFIL
Date   Source Headline
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.